Grandeur Peak Global Advisors LLC Invests $2.91 Million in RxSight, Inc. (NASDAQ:RXST)

Grandeur Peak Global Advisors LLC purchased a new stake in RxSight, Inc. (NASDAQ:RXST - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 84,560 shares of the company's stock, valued at approximately $2,907,000. Grandeur Peak Global Advisors LLC owned 0.21% of RxSight as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Mountain Capital Investment Advisors Inc. boosted its position in shares of RxSight by 3.8% during the fourth quarter. Mountain Capital Investment Advisors Inc. now owns 8,779 shares of the company's stock worth $302,000 after buying an additional 320 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of RxSight by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company's stock worth $1,034,000 after purchasing an additional 399 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of RxSight by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 26,574 shares of the company's stock valued at $914,000 after purchasing an additional 445 shares during the period. Legal & General Group Plc grew its holdings in shares of RxSight by 1.2% in the fourth quarter. Legal & General Group Plc now owns 42,445 shares of the company's stock valued at $1,459,000 after purchasing an additional 512 shares in the last quarter. Finally, F M Investments LLC lifted its holdings in RxSight by 12.6% during the 4th quarter. F M Investments LLC now owns 5,901 shares of the company's stock worth $203,000 after buying an additional 659 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Trading Down 0.6 %

Shares of NASDAQ RXST traded down $0.08 during trading hours on Thursday, reaching $14.45. The stock had a trading volume of 297,569 shares, compared to its average volume of 611,504. The firm has a market cap of $585.09 million, a price-to-earnings ratio of -17.40 and a beta of 1.26. RxSight, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $66.54. The firm has a 50-day moving average of $24.48 and a 200-day moving average of $35.60.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The business had revenue of $40.21 million for the quarter, compared to analysts' expectations of $40.23 million. On average, equities analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Transactions at RxSight

In other RxSight news, Director Shweta Maniar sold 3,519 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the sale, the director now directly owns 7,383 shares of the company's stock, valued at approximately $227,913.21. This trade represents a 32.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Piper Sandler started coverage on RxSight in a research note on Tuesday. They issued a "neutral" rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $17.00 price target (down previously from $40.00) on shares of RxSight in a research report on Friday, April 4th. Wells Fargo & Company decreased their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating for the company in a research note on Thursday, April 3rd. UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and cut their target price for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Finally, Bank of America reiterated an "underperform" rating and issued a $22.00 price target (down previously from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $37.60.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.